

## Physiological and Pharmacological Influences on Thyroxine to 3,5,3'-Triiodothyronine Conversion and Nuclear 3,5,3'-Triiodothyronine Binding in Rat Anterior Pituitary

R. G. Cheron, ... , M. M. Kaplan, P. R. Larsen

*J Clin Invest.* 1979;64(5):1402-1414. <https://doi.org/10.1172/JCI109598>.

### Research Article

Our recent *in vivo* studies have suggested that intrapituitary l-thyroxine ( $T_4$ ) to 3,5,3'-triiodo-l-thyronine ( $T_3$ ) conversion with subsequent nuclear binding of  $T_3$  is an important pathway by which circulating  $T_4$  can inhibit thyrotropin release. The present studies were performed to evaluate various physiological and pharmacological influences on these two processes in rat anterior pituitary tissue. Intact pituitary fragments were incubated in buffer—1% bovine serum albumin containing 0.14 ng/ml [ $^{131}$ I] $T_3$  and 3.8 ng/ml [ $^{125}$ I] $T_4$ . Nuclei were isolated after 3 h of incubation and the bound iodothyronines identified by paper chromatography. There was 0.3-1% [ $^{125}$ I] $T_3$  contaminating the medium [ $^{125}$ I] $T_4$ , and this did not change during incubation. Nuclear [ $^{125}$ I] $T_4$  was not decreased by 650-fold excesses of medium  $T_3$  or  $T_4$ , suggesting that it was nonspecifically bound. The ratio of nuclear to medium [ $^{131}$ I]- and [ $^{125}$ I] $T_3$  were expressed as nuclear counts per minute per milligram wet weight of tissue:counts per minute per microliter medium. Intrapituitary  $T_4$  to  $T_3$  conversion was evidenced by the fact that the nuclear:medium (N:M) ratio for [ $^{131}$ I] $T_3$  was  $0.45 \pm 0.21$ , whereas that for [ $^{125}$ I] $T_3$  was  $2.23 \pm 1.28$  (mean  $\pm$  SD,  $n = 51$ ). A ratio (R), the N:M [ $^{125}$ I] $T_3$  divided by the N:M [ $^{131}$ I] $T_3$ , was used as an index of intrapituitary  $T_4$  to  $T_3$  conversion. Increasing medium  $T_3$  concentrations up to 50 ng/ml caused a progressive decrease in the N:M ratio for both  $T_3$  isotopes, [...]

Find the latest version:

<https://jci.me/109598/pdf>



# Physiological and Pharmacological Influences on Thyroxine to 3,5,3'-Triiodothyronine Conversion and Nuclear 3,5,3'-Triiodothyronine Binding in Rat Anterior Pituitary

R. G. CHERON, M. M. KAPLAN, and P. R. LARSEN, *Howard Hughes Medical Institute Laboratory, Thyroid Unit, Department of Medicine, Peter Bent Brigham Hospital, and Harvard Medical School, Boston, Massachusetts 02115*

**ABSTRACT** Our recent *in vivo* studies have suggested that intrapituitary L-thyroxine ( $T_4$ ) to 3,5,3'-triiodo-L-thyronine ( $T_3$ ) conversion with subsequent nuclear binding of  $T_3$  is an important pathway by which circulating  $T_4$  can inhibit thyrotropin release. The present studies were performed to evaluate various physiological and pharmacological influences on these two processes in rat anterior pituitary tissue. Intact pituitary fragments were incubated in buffer—1% bovine serum albumin containing 0.14 ng/ml [ $^{131}\text{I}$ ] $T_3$  and 3.8 ng/ml [ $^{125}\text{I}$ ] $T_4$ . Nuclei were isolated after 3 h of incubation and the bound iodothyronines identified by paper chromatography. There was 0.3–1% [ $^{125}\text{I}$ ] $T_3$  contaminating the medium [ $^{125}\text{I}$ ] $T_4$ , and this did not change during incubation. Nuclear [ $^{125}\text{I}$ ] $T_4$  was not decreased by 650-fold excesses of medium  $T_3$  or  $T_4$ , suggesting that it was nonspecifically bound. The ratio of nuclear to medium [ $^{131}\text{I}$ ]- and [ $^{125}\text{I}$ ] $T_3$  were expressed as nuclear counts per minute per milligram wet weight of tissue:counts per minute per microliter medium. Intrapituitary  $T_4$  to  $T_3$  conversion was evidenced by the fact that the nuclear:medium (N:M) ratio for [ $^{131}\text{I}$ ] $T_3$  was  $0.45 \pm 0.21$ , whereas that for [ $^{125}\text{I}$ ] $T_3$  was  $2.23 \pm 1.28$  (mean  $\pm$  SD,  $n = 51$ ). A ratio (R), the N:M [ $^{125}\text{I}$ ] $T_3$  divided by the N:M [ $^{131}\text{I}$ ] $T_3$ , was used as an index of intrapituitary  $T_4$  to  $T_3$  conversion. Increasing medium  $T_3$  concentrations up to 50 ng/ml caused a progressive decrease in the N:M ratio for both  $T_3$  isotopes, but no change in the value for R, indicating that both competed for the same limited-capacity nuclear receptors. In-

creasing concentrations of medium  $T_4$  caused no change in the N:M [ $^{131}\text{I}$ ] $T_3$  but did cause a significant decrease in R in three of four experiments. These results suggest saturation of  $T_4$ -5'-monodeiodination occurred at lower  $T_4$  concentrations than saturation of nuclear  $T_3$  binding sites. In hypothyroid rats, the N:M ratios for both [ $^{131}\text{I}$ ] $T_3$  and [ $^{125}\text{I}$ ] $T_3$  were increased ( $P < 0.005$ ), but R was three-fold higher than in controls ( $P < 0.005$ ). Animals given 10  $\mu\text{g}$   $T_4$ /100 g body wt per d for 5 d had significantly decreased N:M ratios for both [ $^{131}\text{I}$ ] $T_3$  and [ $^{125}\text{I}$ ] $T_3$ , as well as a decreased value for R. In fasted rats, neither N:M ratio was depressed, although hepatic  $T_4$  to  $T_3$  conversion in the same animals was 50% of control ( $P < 0.005$ ). Iopanoic acid (13  $\mu\text{M}$ ), but not 6-*n*-propylthiouracil (29  $\mu\text{M}$ ), decreased the N:M [ $^{125}\text{I}$ ] $T_3$  with a significant decrease in the value for R ( $P < 0.025$  or less). Neither sodium iodide (6  $\mu\text{M}$ ) nor thyrotropin-releasing hormone (7-700 nM) affected the  $T_3$  N:M ratios. These results indicate that intrapituitary  $T_4$  to  $T_3$  conversion is stimulated in hypothyroidism and depressed in  $T_4$ -treated animals, whereas opposite changes occur in hepatic  $T_4$ -5'-monodeiodination. Unlike liver, anterior pituitary  $T_4$ -5'-monodeiodination is not affected by fasting or incubation with 6-*n*-propyl-2-thiouracil, but  $T_4$  to  $T_3$  conversion is inhibited in both by iopanoic acid. These results indicate that there are important differences between anterior pituitary and other tissues in the regulation of  $T_4$ -5'-monodeiodination.

## INTRODUCTION

Recent *in vivo* studies from our laboratory have demonstrated a quantitative and chronological relationship between the occupancy of the nuclear iodothyronine receptor of the anterior pituitary tissue

This material was presented in part at the 52nd Annual Meeting of the American Thyroid Association, 13–16 September 1978, Portland, Oregon.

Received for publication 9 February 1979 and in revised form 22 June 1979.

by 3,5,3'-triiodo-L-thyronine ( $T_3$ )<sup>1</sup> and the acute suppression of thyrotropin (TSH) release in hypothyroid rats (1, 2). Moreover, the acute TSH suppression observed after infusion of L-thyroxine ( $T_4$ ) was accompanied by intrapituitary conversion of  $T_4$  to  $T_3$  that was so rapid, virtually all of the acute effect of  $T_4$  on suppression of TSH release could be explained on the basis of the  $T_3$  produced (1, 2). In more recent studies, we have demonstrated that in the euthyroid rat,  $\approx 50\%$  of specifically bound pituitary nuclear  $T_3$  derives from plasma  $T_3$ , and the remaining 50% appears to originate from intrapituitary  $T_4$  to  $T_3$  conversion (3). The total saturation of available nuclear  $T_3$  receptors in the euthyroid rat anterior pituitary was estimated to be 78%, a saturation significantly higher than that of hepatic and kidney nuclear  $T_3$  receptors in the same animals ( $\approx 50\%$ ) (3). This provides a possible explanation for the increased secretion of TSH in response to a decrease in plasma  $T_4$  concentration even when plasma  $T_3$  remains constant. This combination of developments is often observed in patients in the early phases of thyroid gland failure and in those with endemic goiter. If this hypothesis is correct, then the regulation of intrapituitary  $T_4$  to  $T_3$  conversion and control of the binding of the  $T_3$  produced to the specific nuclear thyroid hormone receptor constitute an important means for modulation of the thyroid hormone feedback on the pituitary thyrotroph. The following studies were undertaken to evaluate the uptake of  $T_4$ , its conversion to  $T_3$ , and the subsequent nuclear binding of the  $T_3$  produced in anterior pituitary tissue *in vitro*. In a recent preliminary report, we have described the *in vitro* system used in the present study and provided data indicating that *in vitro*  $T_4$  to  $T_3$  conversion is readily detectable using this method (4).

## METHODS

*Preparation and incubation of pituitary tissue.* Anterior pituitaries from 300 to 450-g male, Sprague-Dawley rats (Zivic-Miller Laboratories, Allison Park, Pa.) were removed, cut into quarters, and incubated in modified Gey and Gey buffer containing 1 mg/ml D-glucose, and 10 mg/ml bovine serum albumin (BSA) as previously described (4). About 30 min preincubation time was required for the collection and randomization of tissue fragments. The 400- $\mu$ l incubation volume contained 5–11 mg anterior pituitary tissue, 2  $\mu$ Ci of [<sup>125</sup>I] $T_4$  (specific activity 1,200–1,400  $\mu$ Ci/ $\mu$ g), and 0.2  $\mu$ Ci [<sup>131</sup>I] $T_3$  (specific activity 3,500  $\mu$ Ci/ $\mu$ g). The gravimetric iodothyronine concentrations were  $\approx 3.8$  ng  $T_4$ /ml and 0.14 ng  $T_3$ /ml, based on these specific activities, except where otherwise specified. The free fraction of  $T_4$  in the 1% BSA-buffer solution was  $0.32 \pm 0.02\%$  (mean  $\pm$  SE) and the

free fraction of  $T_3$  was  $2.3 \pm 0.15\%$  as determined by equilibrium dialysis (5). Neither free fraction was altered in the presence of 50 ng/ml  $T_3$  or 75 ng/ml  $T_4$ .

*Isolation of nuclei, identification of isotopes, and calculations.* After a customary 3-h incubation at 37°C, the pituitary fragments were homogenized in 2.5 ml 0.3 M sucrose/1.1 mM MgCl<sub>2</sub> in a glass homogenizer and nuclei were isolated by centrifugation at 1,000 g. Nuclei were washed twice in 2.5 ml sucrose-MgCl<sub>2</sub> containing 0.5% Triton X-100 (Rohm and Haas Co., Philadelphia, Pa.) and once in 2.5 ml 0.15 M NaCl. Tubes were kept at 4°C throughout. In early studies, nuclear iodothyronines were extracted in 2 ml butanol:2 N HCl (9:1) (37°C for 30 min). The acid:butanol was dried under N<sub>2</sub> at 37°C and redissolved in 100  $\mu$ l of ethanol:concentrated NH<sub>4</sub>OH (99:1), which contained 100  $\mu$ g of  $T_3$ ,  $T_4$ , and NaI. These ethanol extracts were applied directly to Whatman 3 MM chromatography strips (Fisher Scientific Co., Pittsburgh, Pa.), which were then developed for 24 h in tertiary amyl alcohol:hexane:NH<sub>4</sub>OH as previously described (4, 6). This procedure does not result in the formation of the butyl ester of  $T_4$  as shown by control studies performed with [<sup>125</sup>I] $T_4$  added to isolated nuclei. In later experiments (about two-thirds of those reported here), the acid-butanol step was omitted, and the nuclear iodothyronines were extracted directly into the ethanol:NH<sub>4</sub>OH-containing  $T_3$ ,  $T_4$ , and NaI. These two methods gave identical results with 75–90% recovery of [<sup>131</sup>I] $T_3$ . No correction was made for these losses. We previously demonstrated that this chromatographic procedure results in the appearance of <0.4% of [<sup>125</sup>I] $T_4$  as [<sup>125</sup>I] $T_3$  (6). In some experiments (Table I), [<sup>125</sup>I] $T_3$  and [<sup>131</sup>I] $T_3$  were identified in the extranuclear fractions by adding 1.8 ml of the 2.5 ml supernate of the first 1000 g centrifugation to the  $T_3$  antibody-Sepharose (Pharmacia Fine Chemicals, Piscataway, N. J.) conjugate (7). After overnight incubation, the conjugates were washed as previously described, and the labeled hormones were eluted in MeOH:2 N NH<sub>4</sub>OH (99:1, vol/vol) and chromatographed as described above (7). The chromatographs of nuclear and extranuclear fractions were counted at the same time to facilitate calculation of the nuclear:extranuclear ratio for each  $T_3$  isotope.

The percent contamination of [<sup>125</sup>I] $T_4$  with [<sup>125</sup>I] $T_3$  was quantitated by methods previously described, employing affinity chromatography with specific anti- $T_3$ -Sepharose conjugates as a preliminary purification step (7). The percentage of [<sup>125</sup>I] $T_3$  in the [<sup>125</sup>I] $T_4$  ranged from 0.3 to 1% of the total radioactivity and did not change significantly during the incubation as estimated in quadruplicate in four separate experiments (4). Therefore, the [<sup>125</sup>I] $T_3$  present at the start of the incubation was generally used as the medium [<sup>125</sup>I] $T_3$  concentration in the calculation of the nuclear:medium ratios for [<sup>125</sup>I] $T_3$ . However, in those four experiments in which [<sup>125</sup>I] $T_3$  was determined in the medium after incubation, that result was used (see Appendix).

To facilitate discussion of the results, the following terminology has been employed: nuclear  $T_3$ ( $T_3$ ) denotes nuclear [<sup>131</sup>I] $T_3$  derived from medium [<sup>131</sup>I] $T_3$ ; nuclear  $T_3$ ( $T_4$ ) is nuclear [<sup>125</sup>I] $T_3$  derived either from [<sup>125</sup>I] $T_3$  contaminating the [<sup>125</sup>I] $T_4$  in the incubation medium or from [<sup>125</sup>I] $T_4$  5'-monodeiodination in the anterior pituitary tissue. The nuclear:medium (N:M) ratio for both  $T_3$  isotopes is expressed as counts per minute nuclear  $T_3$  per milligram wet weight of tissue divided by counts per minute medium  $T_3$  per microliter. In our previous report, these ratios were calculated in terms of nuclear DNA rather than wet weight. However, because we found the DNA per milligram wet weight to be quite consistent between experiments ( $7.1 \pm 0.48$   $\mu$ g DNA per milligram wet weight, mean  $\pm$  SD,  $n = 26$ ), the pres-

<sup>1</sup>Abbreviations used in this paper: BSA, bovine serum albumin; N:M, nuclear medium ratio; PTU, 6-n-propyl-2-thiouracil; R, N:M  $T_3$ ( $T_4$ )  $\div$  N:M  $T_3$ ( $T_3$ );  $T_3$ , 3,5,3'-triiodo-L-thyronine;  $T_4$ , L-thyroxine; TRH, thyrotropin-releasing hormone; TSH, thyrotropin.

ent results are expressed on a weight basis. 75–83% of pituitary DNA is recovered using this technique. No correction was made for this loss. The N:M ratios, expressed as milligrams wet weight were not different in fragments of different sizes within the ranges used in these experiments.

To demonstrate that significant T<sub>4</sub> 5'-monodeiodination has occurred within the pituitary tissue, the N:M ratio for T<sub>3</sub>(T<sub>4</sub>) must exceed that for T<sub>3</sub>(T<sub>3</sub>). This can be quantitated from the ratio: N:M T<sub>3</sub>(T<sub>4</sub>) ÷ N:M T<sub>3</sub>(T<sub>3</sub>). This ratio has been abbreviated as R. The inverse of R is the fraction of the nuclear T<sub>3</sub>(T<sub>4</sub>) that has derived from cellular uptake and nuclear binding of the [<sup>125</sup>I]T<sub>3</sub> contaminating the [<sup>125</sup>I]T<sub>4</sub> in the medium.

*Miscellaneous.* Hepatic T<sub>4</sub> 5'-monodeiodination was quantitated as previously described (8), and serum T<sub>4</sub> and T<sub>3</sub> were measured by radioimmunoassay (9–11). Chemicals were obtained from the following sources: iopanoic acid was kindly donated by Dr. F. C. Nachod of Sterling-Winthrop Research Institute, Rensselaer, N. Y.; 6-*n*-propyl-2-thiouracil (PTU) was obtained from Aldrich Chemical Co., Inc., Milwaukee, Wis.; BSA (fraction V) from Arnel Products, Brooklyn, N. Y.; [<sup>125</sup>I]T<sub>4</sub> from New England Nuclear, Boston, Mass.; and T<sub>3</sub> (free acid) and thyrotropin-releasing hormone (TRH) from Sigma Chemical Co., St. Louis, Mo. PTU and iopanoic acid were dissolved in warm (37°C) H<sub>2</sub>O at concentrations of 0.2 mg/ml. T<sub>4</sub> and T<sub>3</sub> were initially dissolved in 0.01 M NaOH (1 mg/ml) before dilution and addition to the experimental buffers. [<sup>131</sup>I]T<sub>3</sub> was synthesized by the method of Weeke and Orskov (12). All statistical analyses were by unpaired Student's *t* test.

## RESULTS

*Methodological considerations.* In Table I are shown data indicating that there is no alteration in the extranuclear (cytosol):medium ratio for [<sup>131</sup>I]T<sub>3</sub> resulting from increasing the medium T<sub>3</sub> concentration to as high as 1,000 ng/ml. This indicates that there is no saturation of T<sub>3</sub> transport into the cytosol at the concentrations of T<sub>3</sub> used in these studies. Therefore, the reduction in the nuclear:extranuclear ratio for [<sup>131</sup>I]T<sub>3</sub> found when the medium T<sub>3</sub> concentration is increased from 0.14 to 12.5 ng/ml (right-hand portion

of Table I) would be identical to the relative reduction in the N:M ratio for [<sup>131</sup>I]T<sub>3</sub>. Similar dose-independent and rapid equilibration between plasma and hepatic extranuclear T<sub>3</sub> in rats has been demonstrated *in vivo* by Oppenheimer et al. (13). The data in the last two columns of Table I also indicate that both T<sub>3</sub> isotopes are distributed in the same proportion between nuclear and extranuclear compartments within the tissue. Thus, the [<sup>131</sup>I]T<sub>3</sub> derived from the medium and the [<sup>125</sup>I]T<sub>3</sub> derived both from the medium and from intracellular T<sub>4</sub> 5'-monodeiodination mix completely inside the cell. We have also demonstrated that this is the case in anterior pituitary *in vivo* (2). These two observations provide the theoretical basis for the use of the N:M ratios of these two T<sub>3</sub> isotopes in the evaluation of pituitary T<sub>4</sub> 5'-monodeiodination *in vitro*. In this experiment (Table I) in which each flask contained 7–9 mg of tissue, 8.5±0.4% (mean±SE) of the total [<sup>131</sup>I]T<sub>3</sub> in the flask was in the tissue. These results are typical of this experimental system.

In Table II are shown results of typical studies designed to evaluate the specificity of nuclear binding of both labeled iodothyronines in this system. The results in the upper portion of Table II indicate that as medium T<sub>4</sub> concentrations were increased from 1.3 to 2,500 ng/ml, there was a marked decrease in the quantity of both [<sup>131</sup>I]T<sub>3</sub>(T<sub>3</sub>) and [<sup>125</sup>I]T<sub>3</sub>(T<sub>4</sub>) bound to the pituitary nuclei. In the presence of 2,500 ng T<sub>4</sub>/ml, the counts of each were <20% of those present at the lowest T<sub>4</sub> concentration. There was no significant change in the quantity of nuclear [<sup>125</sup>I]T<sub>4</sub> over this concentration range. These results indicate that T<sub>3</sub> is specifically bound to limited-capacity nuclear binding sites, whereas the binding of T<sub>4</sub> in this system is largely nonspecific. In the lower portion of Table I is shown the effect of increasing concentrations of medium T<sub>3</sub> on the same parameters. As before, the quan-

TABLE I  
Distribution of [<sup>131</sup>I]T<sub>3</sub> and [<sup>125</sup>I]T<sub>3</sub> between Tissue and Medium and between Nuclear and Extranuclear Compartments in Pituitary Fragments Incubated for 3 h *In Vitro*

Condi- tions	Number of incubation vessels	Medium T <sub>3</sub>  ng/ml	Medium T <sub>4</sub>  ng/ml	Extranuclear [ <sup>131</sup> I]T <sub>3</sub> * Medium [ <sup>131</sup> I]T <sub>3</sub>  cpm/mg wet weight cpm/μl medium	Nuclear T <sub>3</sub> Extranuclear T <sub>3</sub> *	
					[ <sup>131</sup> I]T <sub>3</sub>	[ <sup>125</sup> I]T <sub>3</sub>
A	4	0.14	3.8	2.54±0.17	0.16±0.01	0.16±0.03 (NS)‡
B	4	12.5	3.8	2.77±0.24 (NS)§	0.025±0.003	0.032±0.002 (NS)‡
C	4	1,000	3.8	2.78±0.31 (NS)§	—	—

\* The extranuclear [<sup>131</sup>I]T<sub>3</sub> is that in the supernate of the initial 1,000 g centrifugation of the tissue homogenate in 0.32 M sucrose. The T<sub>3</sub> in this fraction is 70–80% of the total extranuclear T<sub>3</sub>. The remainder is found in the second and third sucrose-Triton-MgCl<sub>2</sub> washes.

‡ Not significantly different from the ratio for [<sup>131</sup>I]T<sub>3</sub> by paired *t* test.

§ Not significantly different from the results for A by unpaired *t* test.

TABLE II  
Specificity of Pituitary Nuclear Binding of T<sub>4</sub> and T<sub>3</sub> Derived Either  
from the Medium or from Intrapituitary T<sub>4</sub> Monodeiodination

Nuclear Iodothyronine*			
<i>cp5m</i>			
Experiment A			
Medium T <sub>4</sub> , ng/ml ‡	1.25	75	2,500
[ <sup>131</sup> I]T <sub>3</sub> (T <sub>3</sub> )	4,586±218	2,716±318	795±133
[ <sup>125</sup> I]T <sub>4</sub>	4,237±621	4,109±203	3,709±491
[ <sup>125</sup> I]T <sub>3</sub> (T <sub>4</sub> )	1,147±220	606±445	88±7
Experiment B			
Medium T <sub>3</sub> , ng/ml §	0.14	12.5	2,500
[ <sup>131</sup> I]T <sub>3</sub> (T <sub>3</sub> )	7,157±928	2,155±226	367±40
[ <sup>125</sup> I]T <sub>4</sub>	8,597±1,937	7,359±1,306	6,818±799
[ <sup>125</sup> I]T <sub>3</sub> (T <sub>4</sub> )	3,268±296	1,220±125	109±24

\* Mean±SEM of triplicate samples incubated 3 h.

‡ Medium T<sub>3</sub> constant, 0.14 ng/ml.

§ Medium T<sub>4</sub> constant, 3.8 ng/ml.

tities of T<sub>3</sub>(T<sub>3</sub>) and T<sub>3</sub>(T<sub>4</sub>) bound to the nuclei diminished as medium T<sub>3</sub> concentration was increased. The fraction of T<sub>3</sub> bound in the presence of 2,500 ng/ml concentrations of T<sub>3</sub> is ≈5% of that in the presence of 0.14 ng T<sub>3</sub>/ml, and similar results were obtained for T<sub>3</sub>(T<sub>4</sub>). Increasing T<sub>3</sub> had little, if any, effect on the quantities of [<sup>125</sup>I]T<sub>4</sub> bound to the nucleus, again suggesting that it was not bound to the same limited-capacity sites as was T<sub>3</sub>. The ratio of the nuclear counts of [<sup>125</sup>I]T<sub>4</sub> to [<sup>125</sup>I]T<sub>3</sub> in both sets of experiments is generally <10:1, except at extremely high T<sub>3</sub> or T<sub>4</sub> concentrations. Thus, under the conditions used in these studies, there was no significant contribution of artifactual T<sub>4</sub> 5'-monodeiodination during the paper chromatographic separation of the extracted nuclear iodothyronines to the estimated [<sup>125</sup>I]T<sub>3</sub> (4, 6, 7).

These results suggest that the bulk of the [<sup>125</sup>I]T<sub>4</sub> found in the nuclear fraction was present as a result of contamination of nuclei with incubation medium and/or cytosol. To evaluate this, pituitaries were incubated in the presence of <sup>131</sup>I-labeled BSA and [<sup>125</sup>I]T<sub>4</sub> in the presence of 2,500 ng T<sub>4</sub>/ml. No <sup>131</sup>I-BSA was found in the nuclei, indicating that the [<sup>125</sup>I]T<sub>4</sub> present must have come from cytosol. Because of the large fraction of T<sub>4</sub> that is "non-specifically" bound, it was not possible to determine whether there was specifically bound nuclear T<sub>4</sub> in this system, and this will not be discussed further. To calculate specifically bound nuclear T<sub>3</sub>, nonspecifically bound T<sub>3</sub> should be deducted from the total. However, because this was <10% of that bound in the presence of 0.14 ng T<sub>3</sub>/ml (Table II), this correction was not performed for either [<sup>131</sup>I]T<sub>3</sub> or [<sup>125</sup>I]T<sub>3</sub> N:M ratios.

In Table III are presented studies of the relationship between the duration of incubation and the N:M

ratios for T<sub>3</sub>(T<sub>3</sub>) and T<sub>3</sub>(T<sub>4</sub>). In experiment A the N:M ratio for T<sub>3</sub>(T<sub>3</sub>) increases rapidly to an apparent plateau by 4 h. However, in experiments B and C there was a further increase of 25–50% in the N:M T<sub>3</sub>(T<sub>3</sub>) ratio over the subsequent 3- to 5-h period. The N:M ratio of T<sub>3</sub>(T<sub>4</sub>) showed a somewhat different pattern. In experiment A this ratio was not significantly different from that for T<sub>3</sub>(T<sub>3</sub>) until 2 h of incubation, and the ratio continued to increase up to the 4th h. The increase in the N:M T<sub>3</sub>(T<sub>4</sub>) relative to the N:M (T<sub>3</sub>(T<sub>3</sub>) is reflected in a rising value for R. In experiments B and C there were further increases in R with longer incubations up to 8 h. We attempted to evaluate the effects of incubation for longer periods, but the tissue did not

TABLE III  
Relationship of the Duration of Incubation to the N:M  
Ratios for T<sub>3</sub>(T<sub>3</sub>) and T<sub>3</sub>(T<sub>4</sub>)

Experiment	Incubation time <i>h</i>	N:M ratios*		
		T <sub>3</sub> (T <sub>3</sub> )	T <sub>3</sub> (T <sub>4</sub> )	R
A	1	0.16±0.006	0.18±0.009	1.11±0.04
	2	0.31±0.01	0.79±0.041	2.51±0.1
	3	0.33±0.022	1.17±0.171	3.51±0.40
	4	0.34±0.027	1.37±0.081	4.01±0.16
B	3	0.66±0.025	2.96±0.240	4.51±0.34
	6	0.95±0.069	6.54±0.591	6.95±0.51
	8	1.08±0.047	9.94±0.750	9.19±0.30
C	3	0.84±0.108	6.29±0.454	7.64±0.49
	6	1.17±0.193	14.27±1.564	12.35±0.62

\* Mean±SEM of triplicate incubations.

appear to be viable, and results were inconclusive. As there did not appear to be qualitative differences in the ratios with longer incubation times, we generally used a 3-h interval, recognizing that this was not a true equilibrium value, at least not for the N:M  $T_3(T_4)$ .

It is apparent from Tables II and III that there was considerable variation from experiment to experiment in the N:M ratios. The N:M  $T_3(T_3)$  was  $0.45 \pm 0.21$  (mean  $\pm$  SD), the N:M  $T_3(T_4)$   $2.23 \pm 1.28$ , and R was  $5.42 \pm 3.46$  in 51 individual control flasks. However, the reproducibility within a given experiment was quite satisfactory (see below). Accordingly, control pituitaries from euthyroid rats were included in all experiments described. The fraction of cellular [ $^{131}I$ ]  $T_3$  that was bound to nuclei was quantitated in three experiments at medium  $T_3$  concentrations of 0.14 ng  $T_3$ /ml. The specifically bound nuclear [ $^{131}I$ ]  $T_3$  was  $18 \pm 1$ ,  $18 \pm 3$ , and  $24 \pm 2\%$  (all results mean  $\pm$  SD of triplicates) of the total homogenate [ $^{131}I$ ]  $T_3$ . The mean of the results of the three experiments was 20%.

Inasmuch as anterior pituitary tissue contains both  $T_3$  and  $T_4$ , it was of interest to determine the rate at which these endogenous hormones were released into the incubation medium. Depending on the total quantities involved, this could alter the estimated specific activity of the iodothyronines. To evaluate this, rats were given tracer  $T_3$  or  $T_4$  in vivo, and their anterior pituitaries were removed 1 h later. The exit of  $T_3$  and  $T_4$  into the medium was quantitated under the standard experimental conditions used. During the tissue collection and preincubation period ( $\approx 30$  min),  $\approx 20\%$  of tracer  $T_3$  was released. Over the subsequent 3 h incubation, a further 60–80% of the total pituitary  $T_3$  appeared in the medium. About 50% of tracer  $T_4$  exited during the preincubation period, and the remainder during the subsequent 3 h. Current estimates of total pituitary iodothyronines suggest that there are about 23 pg of  $T_4$  and about 45 pg of  $T_3$ /7 mg of pituitary tissue (14, 15). Assuming complete mixing of pituitary iodothyronines with those in the medium, the decrease in the specific activity is negligible for  $T_4$  and  $\approx 25\%$  for  $T_3$  for euthyroid rats.

*Effects of altering concentrations of medium iodothyronines on N:M ratios for  $T_3(T_3)$  and  $T_3(T_4)$ .* Results of studies of the effects of increasing concentrations of medium iodothyronines are shown in Tables IV and V. Since the specific nuclear receptor sites have limited binding capacity for  $T_3$  in vivo and in vitro (Table II), one would anticipate that increasing medium  $T_3$  concentrations would lead to decreases in both N:M ( $T_3(T_3)$ ) and N:M  $T_3(T_4)$  if these two species are competing for the same nuclear receptor site. This prediction is borne out in the experiments shown in Table IV. A significant reduction in the N:M  $T_3(T_3)$  and N:M  $T_3(T_4)$  was achieved in experiment A at 2.5

ng  $T_3$ /ml and in experiments C and D at 12.5 ng  $T_3$ /ml. Although there are also apparent decreases in both N:M ratios in experiments B and E, these differences did not achieve statistical significance in the triplicate samples. In no experiment was the R value different from that at the lowest  $T_3$  concentration of 0.14 ng  $T_3$ /ml.

The effects of increasing medium  $T_4$  concentrations were considerably different (Table V). In none of the four experiments were significant differences found in the N:M  $T_3(T_3)$  ratio with medium  $T_4$  concentrations up to 75 ng/ml. Changes in the N:M ratio for  $T_3(T_4)$  were also not significant at any of these  $T_4$  concentrations. However, there was a numerical decrease in the N:M  $T_3(T_4)$  at the highest concentration of  $T_4$  used in all experiments. This change is reflected in a decrease in the value for R that was statistically significant in three of the four experiments. These results suggest that there is saturation of the pathway for generating nuclear  $T_3(T_4)$  before saturation of the nuclear receptor sites by the  $T_3$  present in the  $T_4$  or by that generated from it. The more ready saturation of the nuclear receptors with  $T_3$ , as opposed to  $T_4$ , is reflected in the fact that there is little, if any, decrease in the N:M  $T_3(T_3)$  at medium  $T_4$  concentrations which are five- and sixfold in excess of those at which a  $T_3$  effect was usually observed.

*Effects of alterations in thyroid status on pituitary  $T_4$  5'-monodeiodination and nuclear binding.* Hypothyroidism has been shown to reduce and  $T_4$  administration to increase, the rate of 5'-monodeiodination in rat liver (16). To examine the effects of altered thyroid status on  $T_4$  to  $T_3$  conversion in the anterior pituitary, animals were given 10  $\mu$ g  $T_4$ /100 g body wt per d for 5 d subcutaneously or were thyroidectomized 2–3 mo before the study (Table VI). In  $T_4$ -treated animals, the N:M ratio for  $T_3(T_3)$  was slightly but significantly reduced from that present in euthyroid control animals from the same group. An even greater reduction was observed in the N:M ratios for  $T_3(T_4)$ , which were  $<50\%$  of those observed in simultaneously studied controls. As a result, the value for R in  $T_4$ -treated rat pituitaries was roughly half that obtained in euthyroid rats.

In chronically hypothyroid rats, the N:M ratios for both  $T_3(T_3)$  and  $T_3(T_4)$  were significantly higher than those in controls in the same experiment. The N:M ratio for  $T_3(T_3)$  was nearly twice that of normal animals, and the N:M ratio for  $T_3(T_4)$  was approximately five times that of the controls. The ratio R was increased two- to threefold over that in the euthyroid rats. When compared with the results for all the euthyroid controls (see above), the N:M for  $T_3(T_4)$  and R were also significantly greater in pituitaries from hypothyroid rats,  $P < 0.001$  and  $P < 0.025$ , respectively. However,

TABLE IV  
Effect of Alterations in Medium T<sub>3</sub> Concentrations on the N:M Ratios for T<sub>3</sub>(T<sub>3</sub>)  
and T<sub>3</sub>(T<sub>4</sub>) in Rat Anterior Pituitary Tissue

Medium T <sub>3</sub> , ng/ml	0.14	0.75	2.5	12.5	50
<b>Experiment A*</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.39±0.02	—	0.23±0.02‡	0.11±0.01§	—
N:M T <sub>3</sub> (T <sub>4</sub> )	3.06±0.20	—	2.01±0.12‡	1.11±0.02§	—
R	7.93±0.92	—	8.77±0.27	11.18±1.59	—
<b>Experiment B</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.36±0.06	0.33±0.04	0.26±0.03	0.21±0.05	—
N:M T <sub>3</sub> (T <sub>4</sub> )	1.14±0.27	0.96±0.21	0.78±0.08	0.58±0.12	—
R	3.12±0.14	2.79±0.35	2.95±0.10	2.86±0.50	—
<b>Experiment C</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.53±0.05	—	—	0.14±0.01 <sup>  </sup>	0.09±0.01 <sup>  </sup>
N:M T <sub>3</sub> (T <sub>4</sub> )	1.73±0.09	—	—	0.51±0.06§	0.29±0.03§
R	3.14±0.32	—	—	3.79±0.20	3.48±0.27
<b>Experiment D</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.51±0.03	—	—	0.11±0.01§	0.08±0.02§
N:M T <sub>3</sub> (T <sub>4</sub> )	3.21±0.26	—	—	0.65±0.06§	0.34±0.08§
R	6.28±0.21	—	—	5.92±0.58	4.46±0.25
<b>Experiment E</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.23±0.02	0.27±0.03	0.21±0.06	0.19±0.05	—
N:M T <sub>3</sub> (T <sub>4</sub> )	1.16±0.12	1.13±0.03	0.84±0.36	0.72±0.20	—
R	5.18±0.87	4.22±0.44	3.74±0.65	3.86±0.26	—

Mean±SE of triplicates.

\* Incubation times were 3 h for experiments A–C; 6 h for experiments D and E. Medium T<sub>4</sub>, 3.8 ng/ml.

‡ P values <0.01.

§ P < 0.001 for differences of N:M ratios from those present at medium T<sub>3</sub> concentrations of 0.14 ng/ml (unpaired *t* test).

<sup>||</sup> P < 0.005.

the N:M for T<sub>3</sub>(T<sub>3</sub>) was not significantly higher in the hypothyroid pituitaries than in the total control population. Thus, T<sub>4</sub> treatment decreased and hypothyroidism increased the capacity of the anterior pituitary to deiodinate T<sub>4</sub> to T<sub>3</sub>, effects opposite to those reported for hepatic tissue in similar circumstances.

**Intrapituitary T<sub>4</sub> to T<sub>3</sub> conversion and nuclear binding in fasted rats.** Caloric deprivation results in a reduction in hepatic T<sub>4</sub> 5'-monodeiodination in rats (8, 17–19). The data in Table VII indicate that neither the N:M ratio for T<sub>3</sub>(T<sub>3</sub>) nor that for T<sub>3</sub>(T<sub>4</sub>) were significantly different from control after three night's fasting in 230-g rats. Hepatic T<sub>4</sub> 5'-monodeiodination was also quantitated in the same animals from which these anterior pituitaries were obtained (Table VII). Hepatic T<sub>4</sub> 5'-monodeiodination was reduced to <50% of that in controls (P < 0.005).

**Effects of iopanoic acid, PTU, TRH and NaI on intrapituitary T<sub>4</sub> to T<sub>3</sub> conversion and nuclear binding.** Iopanoic acid and PTU inhibit hepatic 5'-monodeiodination (8, 20–22). Incubation of pituitary

fragments with 13 μM iopanoic acid results in no alteration in the N:M ratio for T<sub>3</sub>(T<sub>3</sub>) but does result in a marked decrease in the N:M ratio for T<sub>3</sub>(T<sub>4</sub>) (Table VIII). For example, in experiment D the amount of T<sub>3</sub>(T<sub>4</sub>) in the nucleus is reduced to that which would be expected on the basis of [<sup>125</sup>I]T<sub>3</sub> contamination alone. The R values for all experiments were <50% of the respective controls. There was no reduction in tissue [<sup>125</sup>I]T<sub>4</sub> uptake by iopanoic acid as judged by nuclear [<sup>125</sup>I]T<sub>4</sub> in these experiments.

Incubation with 29 μM PTU had no demonstrable effect on the N:M for T<sub>3</sub>(T<sub>3</sub>) and did not reduce the N:M T<sub>3</sub>(T<sub>4</sub>) ratio. As a result, R was not lower, and in one case it was statistically higher than in controls from the same pool of pituitary fragments. To investigate the possibility that in vivo treatment of animals with PTU might be required to inhibit T<sub>4</sub> to T<sub>3</sub> conversion, four normal animals were given 2 mg PTU/100 g body wt i.p. twice daily for 2 d before measuring body pituitary and hepatic T<sub>4</sub> to T<sub>3</sub> conversion. As is shown in Table VIII, there is no effect of PTU pretreatment

**TABLE V**  
Effect of Alterations in Medium T<sub>4</sub> Concentrations on the N:M Ratios for T<sub>3</sub>(T<sub>3</sub>) and T<sub>3</sub>(T<sub>4</sub>) in Rat Anterior Pituitary Tissue

Medium T <sub>4</sub> , ng/ml	1.25	3.8	7.5	25	75
<b>Experiment A*</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	—	0.25±0.03	0.29±0.01	0.26±0.01	0.25±0.01
N:M T <sub>3</sub> (T <sub>4</sub> )	—	0.68±0.09	0.97±0.04	0.65±0.03	0.47±0.04
R	—	2.68±0.11	3.32±0.09‡	2.49±0.09	1.87±0.17‡
<b>Experiment B</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.13±0.01	0.17±0.05	0.18±0.04	0.16±0.03	—
N:M T <sub>3</sub> (T <sub>4</sub> )	2.0±0.39	2.10±0.69	2.36±0.82	1.16±0.11	—
R	16.09±2.30	12.88±5.07	14.73±7.33	7.48±0.80‡	—
<b>Experiment C</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.21±0.06	0.28±0.04	0.25±0.05	—	—
N:M T <sub>3</sub> (T <sub>4</sub> )	3.27±0.36	3.16±0.14	2.75±0.22	—	—
R	20.23±4.81	12.23±1.87	11.95±1.85	—	—
<b>Experiment D</b>					
N:M T <sub>3</sub> (T <sub>3</sub> )	0.37±0.07	0.36±0.08	—	0.32±0.03	0.23±0.03
N:M T <sub>3</sub> (T <sub>4</sub> )	3.70±0.57	2.11±0.71	—	0.87±0.07§	0.50±0.22§
R	10.22±1.29	5.64±0.74	—	2.72±0.31 <sup>  </sup>	2.31±1.22‡

Mean±SE of triplicates.

\* Incubation times were 3 h for experiments A–C and 6 h for experiment D.

‡ P < 0.02.

§ P < 0.01.

<sup>||</sup> P < 0.005 for differences of results from those at the lowest medium T<sub>4</sub> concentrations employed in that experiment (unpaired t test).

on pituitary T<sub>4</sub> to T<sub>3</sub> conversion. In these same animals, the hepatic T<sub>4</sub> 5'-deiodination rate was reduced to 12% of the results in controls (P < 0.01, data not shown).

Neither NaI (6 μM) nor TRH had a significant effect on the N:M T<sub>3</sub>(T<sub>3</sub>) or T<sub>3</sub>(T<sub>4</sub>) ratios. The concentrations

of TRH used and the observed values for R were as follows: for 7 nM, R was 3.24±1.87 (mean±SE of triplicates); for 70 nM, R was 1.98±0.22; and for 700 nM, R was 3.33±0.38. The control value for R in this pool of euthyroid pituitaries was 3.81±0.51.

**TABLE VI**  
Comparison of Intrapituitary Monodeiodination in Euthyroid, T<sub>4</sub>-treated and Hypothyroid Rats

Experiment	N:M ratio								
	Euthyroid			T <sub>4</sub> -treated*			Hypothyroid‡		
	T <sub>3</sub> (T <sub>3</sub> )	T <sub>3</sub> (T <sub>4</sub> )	R	T <sub>3</sub> (T <sub>3</sub> )	T <sub>3</sub> (T <sub>4</sub> )	R	T <sub>3</sub> (T <sub>3</sub> )	T <sub>3</sub> (T <sub>4</sub> )	R
A	0.66±0.08	2.47±0.58	3.65±0.50	—	—	—	1.05±0.03§	10.12±0.53§	9.66±0.48§
B	0.34±0.02	1.20±0.15	3.49±0.35	0.26±0.01§	0.52±0.06 <sup>  </sup>	2.01±0.25 <sup>  </sup>	0.62±0.01§	6.11±0.45§	9.84±0.79§
C	0.42±0.04	1.88±0.20	4.50±0.59	0.26±0.01 <sup>  </sup>	0.53±0.02§	2.02±0.05 <sup>  </sup>	—	—	—

Mean±SEM of triplicate determinations.

\* 10 μg T<sub>4</sub>/100 g body wt per d × 5 d subcutaneously. Serum T<sub>4</sub> was 8.9±1.1 (exp. B) and 11.3±1.1 (exp. C) μg/dl. Mean±SEM. Pituitary quarters from three rats were pooled in each experiment and randomly combined (four/flask). Controls were from the same group of rats.

‡ At least 2 mo postsurgical thyroidectomy and parathyroid implantation. Serum T<sub>4</sub> was <0.2 μg/dl for all rats. Pituitary quarters from three rats were pooled in each experiment and randomly combined (four/flask). Control rats were of the same size but not from the same group.

§ P < 0.005 for difference of results from control by unpaired t test.

<sup>||</sup> P < 0.025.

TABLE VII

Comparison of  $T_4$  to  $T_3$  Conversion in Anterior Pituitary and Liver of Fasted Rats

Flask	Control			Fasted*		
	N:M ratio			N:M ratio		
	$T_3(T_3)$	$T_3(T_4)$	R	$T_3(T_3)$	$T_3(T_4)$	R
<b>Anterior pituitary</b>						
1	0.18	1.17	6.62	0.20	1.10	5.39
2	0.21	1.27	5.95	0.28	1.34	4.76
3	0.26	1.61	6.15	0.24	1.29	5.29
4	0.26	1.40	5.42	0.24	1.16	4.82
5	0.22	1.12	5.06	0.14	0.79	5.49
Mean	0.23	1.31	5.84	0.22	1.14	5.15
SEM	0.01	0.01	0.27	0.02	0.01	0.15
<b>Liver, fmol <math>T_3</math>/min/ mg protein</b>						
		n = 8			n = 8	
Mean		46.8			21.9†	
SEM		5.7			2.3	

\* Eight rats were fasted for three nights with eight others from the same shipment as controls. Mean starting weights were 232 and 227 g in fasted and control rats, respectively. Mean weights after 3 d were 182 (fasted) and 254 g (control). Anterior pituitaries were pooled and six quarters placed into each flask. Hepatic  $T_4$  5'-monodeiodination was studied in each individual animal as previously described (8).

†  $P < 0.005$  for difference from control.

TABLE VIII

Effects of Iopanoic Acid and PTU on Intrapituitary  $T_4$  to  $T_3$  Conversion and Nuclear  $T_3$  Binding

	Control			Medium concentration  $\mu M$	Experimental		
	N:M ratio				N:M ratio		
	$T_3(T_3)$	$T_3(T_4)$	R		$T_3(T_3)$	$T_3(T_4)$	R
<b>Iopanoic acid</b>							
Experiment							
A	0.34±0.02	1.20±0.15	3.49±0.35	13	0.46±0.11	0.69±0.15	1.52±0.03*
B	0.42±0.04	1.88±0.20	4.50±0.59	13	0.40±0.04	0.78±0.06	1.99±0.31*
C	0.49±0.02	3.10±0.67	6.54±1.49	13	0.55±0.02*	0.92±0.07†	1.69±0.14†
D	0.83±0.08	5.81±0.93	6.94±0.41	13	0.93±0.03	0.90±0.07†	0.96±0.05†
<b>PTU</b>							
Experiment							
A	0.86±0.08	4.08±0.34	4.78±0.19	29	0.91±0.02	3.98±0.28	4.36±0.32
B	0.30±0.01	0.66±0.08	2.15±0.18	29	0.40±0.05	1.14±0.13*	2.90±0.02*
C	0.83±0.09	5.81±0.93	6.94±0.41	29	0.89±0.05	6.90±0.99	7.73±0.71
D	0.24±0.03	0.64±0.09	2.72±0.26	In vivo‡	0.18±0.02	0.49±0.05	2.81±0.09

Mean±SEM of triplicate determinations.

\*  $P < 0.025$ .

†  $P < 0.005$ ; statistical significance of differences of experimental samples from controls.

‡ PTU, 2 mg/100 g body wt i.p., twice daily for 2 d.

## DISCUSSION

*Methodological considerations and results of basal studies.* The principal advantage of the system described in this report is its capacity to measure small quantities of [ $^{125}\text{I}$ ]T<sub>3</sub> generated from [ $^{125}\text{I}$ ]T<sub>4</sub> in anterior pituitary tissue. Since the distribution of [ $^{131}\text{I}$ ]T<sub>3</sub> and [ $^{125}\text{I}$ ]T<sub>3</sub> is not different within the tissue (Table I), the net T<sub>4</sub> to T<sub>3</sub> conversion in an experiment can be determined from a comparison of the N:M ratios for [ $^{131}\text{I}$ ]T<sub>3</sub> and [ $^{125}\text{I}$ ]T<sub>3</sub>. The value R is a reflection of the difference between these two ratios. In the experiment for which detailed data are provided in the Appendix, R is 4.8 and the [ $^{125}\text{I}$ ]T<sub>3</sub> is 0.8% of the T<sub>4</sub> after the incubation. (Preincubation data were not available for this experiment.) The fraction of the total flask [ $^{131}\text{I}$ ]T<sub>3</sub> in the nuclei is 1.9%. Thus, the fraction of [ $^{125}\text{I}$ ]T<sub>4</sub> as nuclear [ $^{125}\text{I}$ ]T<sub>3</sub> contamination alone is  $1.9 \times 0.8\%$ , or 0.015% of the total [ $^{125}\text{I}$ ]T<sub>4</sub> in the flask. Since R is 4.8, the observed [ $^{125}\text{I}$ ]T<sub>3</sub> in the nuclei is  $4.8 \times 0.015\%$ , or 0.072% of the total [ $^{125}\text{I}$ ]T<sub>4</sub>. The net increment in nuclear [ $^{125}\text{I}$ ]T<sub>3</sub> above that expected from nuclear binding of contaminating [ $^{125}\text{I}$ ]T<sub>3</sub> is 0.072% less 0.015%, or 0.057% of the T<sub>4</sub>. Because we observed that only 20% of the tissue [ $^{131}\text{I}$ ]T<sub>3</sub> is bound to the nuclei in this *in vitro* system (see above), and because the subcellular distribution of [ $^{125}\text{I}$ ]T<sub>3</sub> is not different from that of [ $^{131}\text{I}$ ]T<sub>3</sub> (Table I), this figure must be multiplied by five to estimate the increment in total tissue [ $^{125}\text{I}$ ]T<sub>3</sub> and by two to correct for the loss of specific activity during T<sub>4</sub> 5'-monodeiodination. Thus, the net increment in total T<sub>3</sub> from T<sub>4</sub> in the system is 0.57% of the T<sub>4</sub> present. Virtually all of this [ $^{125}\text{I}$ ]T<sub>3</sub> is still within the tissue after 3 h of incubation. It is apparent that the [ $^{125}\text{I}$ ]T<sub>3</sub> formed in the tissue has not equilibrated with the medium because a 4.8-fold increment in medium [ $^{125}\text{I}$ ]T<sub>3</sub> would be quite simple to recognize, and no significant increment of [ $^{125}\text{I}$ ]T<sub>3</sub> is observed. Although it might be theoretically desirable to determine the net [ $^{125}\text{I}$ ]T<sub>3</sub> produced for each experiment, the data would have no more validity than is achieved more simply by the use of the R value which automatically corrects for any experimentally induced or endogenous differences in nuclear binding and for the modest losses in the isolation and identification of nuclear T<sub>3</sub>. It should be kept in mind that the extranuclear:medium T<sub>3</sub> ratios were tested and found to be the same only for basal conditions and during incubations with 12.5 ng/ml T<sub>3</sub> (Table I). If any of the other manipulations (altered thyroid function or incubation with PTU or iopanoic acid) altered this ratio without affecting [ $^{125}\text{I}$ ]T<sub>4</sub> uptake and conversion, then comparisons with the R value in control tissues would not be valid. The similarity of the N:M ratios for [ $^{131}\text{I}$ ]T<sub>3</sub> under all circumstances makes this possibility seem remote.

It is presumably the small quantities of T<sub>3</sub> generated that account for the failure of previous investigators using either tissue fragments (23) or homogenates (24) to demonstrate conversion in rat anterior pituitary tissue *in vitro*. The technical aspects of the present system that permit the required sensitivity are that: (a) the nuclear receptor acts as a high affinity sink for the [ $^{125}\text{I}$ ]T<sub>3</sub> formed in the tissue, segregating it from [ $^{125}\text{I}$ ]T<sub>4</sub>; (b) the simultaneous incubation with [ $^{131}\text{I}$ ]T<sub>3</sub> allows corrections for transfer of [ $^{125}\text{I}$ ]T<sub>3</sub> from the medium to the nucleus and for identification of any nonspecific effects of the experimental variables on nuclear T<sub>3</sub> binding for each individual tissue; and (c) the sensitivity and precision of affinity chromatography followed by paper chromatography allows quantitation of the amount of [ $^{125}\text{I}$ ]T<sub>3</sub> in the medium, even though it represents only 0.3–1% of the [ $^{125}\text{I}$ ]T<sub>4</sub>.

Data supporting the technical aspects of this method have been discussed (4, 7). Physiological substantiation is provided by the following aspects of the present report. Our previous *in vivo* experiments have shown that pretreatment of rats with amounts of PTU adequate to block  $\approx 70\%$  of total body T<sub>4</sub> to T<sub>3</sub> production neither decreased intrapituitary T<sub>4</sub> to T<sub>3</sub> conversion nor prevented the acute suppression of TSH release by T<sub>4</sub> in chronically hypothyroid rats (2, 25). In the present studies, incubation of pituitary fragments with doses of PTU 10-fold higher than those that block hepatic T<sub>4</sub> 5'-monodeiodination did not affect intrapituitary T<sub>4</sub> to T<sub>3</sub> conversion (8). Treatment of rats with quantities of PTU leading to 88% inhibition of T<sub>4</sub> to T<sub>3</sub> conversion in livers subsequently studied *in vitro* also did not affect pituitary T<sub>4</sub> to T<sub>3</sub> conversion in the *in vitro* system. On the other hand, iopanoic acid—a potent inhibitor of hepatic T<sub>4</sub> to T<sub>3</sub> conversion (8)—can readily block pituitary T<sub>4</sub> to T<sub>3</sub> conversion, even suppressing the R ratio to unity in some experiments (Table VIII). We have recently been able to demonstrate that iopanoic acid treatment of rats also blocks *in vivo* generation of T<sub>3</sub> from T<sub>4</sub> in the anterior pituitary and prevents the decrease in TSH associated with acute T<sub>4</sub> administration (26). Thus, with respect to both pharmacological agents, the response measured in this *in vitro* system is the same as that observed *in vivo*, and the physiological relevance of these results is supported.

There are, however, several aspects of the system which do not appear to be physiological. The data in Table II indicate that substantial quantities of [ $^{125}\text{I}$ ]T<sub>4</sub> are nonspecifically bound to the nucleus, which is not the case *in vivo* (1–3). This may be caused by the high concentrations of cytosolic [ $^{125}\text{I}$ ]T<sub>4</sub> in the *in vitro* incubation system. Equilibrium is also not achieved in these studies, at least with respect to the N:M ratio for T<sub>3</sub>(T<sub>4</sub>) at 3 h (Table III), although this does not appear to change the qualitative aspects of the results.

About 16 h is required for equilibrium to be achieved in vivo between nuclear  $T_3(T_4)$  and plasma  $T_4$  in euthyroid rats (3). The estimated free  $T_4$  and  $T_3$  concentrations in the medium were 12 and 3 pg/ml at  $T_4$  and  $T_3$  concentrations of 3.8 and 0.14 ng/ml. The free hormone fractions obtained with this fraction V BSA preparation are lower than those usually obtained with crystalline BSA because it is a cruder preparation. The free fractions in the medium do not change at the  $T_3$  and  $T_4$  concentrations we have employed. Our studies in normal rats suggest that free  $T_4$  and  $T_3$  concentrations are about 15–25 and 1.1–2.0 pg/ml, respectively (27). The data in Table V suggest that increasing the medium-free  $T_4$  concentration to the upper limits of the normal range might decrease the N:M ratio for  $T_3(T_4)$ , though it would still remain substantially higher than that for  $T_3(T_3)$ .

We have not been able to determine the reason for the relatively wide range of results in euthyroid rats in different experiments. Small differences in the quantities of pituitary iodothyronines would not appear to be sufficient to influence the N:M ratios based on the evidence from Tables IV and V. Furthermore, because the replication within a given experiment is quite satisfactory (e.g., Table VII), the factor(s) responsible for the variation seems to be common to all flasks of a given experiment. We are continuing to investigate this question, but the present results indicate that use of normal controls for each experiment are sufficient for the present conclusions. The absence of an effect of NaI indicates that artifactual labeling of  $T_3$  with  $^{125}\text{I}^-$  does not play a role in the generation of  $^{125}\text{I}]T_3$  in the anterior pituitary, nor does  $\text{I}^-$  inhibit the conversion process per se.

*Effects of  $T_3$  and  $T_4$  on pituitary  $T_4$  monodeiodination and nuclear  $T_3$  binding.* Since the nuclear  $T_3$  receptor binding capacity is limited, the observation (Table IV) that increasing concentrations of medium  $T_3$  decrease both the  $T_3(T_3)$  and  $T_3(T_4)$  N:M ratios is not surprising. That R does not change during this process indicates that the nuclear binding of  $T_3(T_3)$  and  $T_3(T_4)$  are equally affected by increases in tissue  $T_3$ . This suggests that the two  $T_3$  pools,  $T_3$  from the medium and  $T_3$  from intrapituitary  $T_4$  generation, are completely miscible. This is consistent with our previous conclusions based on in vivo studies (2) and with the data in Table I. Secondly, the results also indicate that  $T_3$  itself does not inhibit  $T_4$  to  $T_3$  conversion in anterior pituitary tissue.

The maximum binding capacity for the pituitary nuclear  $T_3$  receptors can be roughly estimated from experiments C and D (Table IV), taking non-specific binding into account. The result is 0.3–0.4 pg  $T_3/\mu\text{g}$  DNA, which is about 50% of the in vivo result (3, 28). This difference may be a reflection of the failure to

reach equilibrium, as well as of impaired tissue function under in vitro conditions. In vitro only 20% of the tissue  $T_3$  is bound to the nuclei, whereas in vivo this figure is  $\approx 50\%$  (28).

The data in Table V show that with increasing medium  $T_4$  concentrations, the  $T_3(T_4)$  N:M ratio falls before that of  $T_3(T_3)$ . This suggests that saturation of either the  $T_4$  5'-monodeiodination process or of tissue uptake of  $T_4$  has occurred. Because we have not found substantial differences in tissue  $^{125}\text{I}]T_4$  (as reflected by nuclear  $^{125}\text{I}]T_4$ ) with increasing medium  $T_4$  concentrations (Table II), we suspect that it is the conversion mechanism that is saturated. The data are not consistent enough to allow accurate estimation of the  $T_4$  concentration at which saturation occurs, but it could be close to the physiological range for free  $T_4$ . The lack of change in the N:M ratio for  $T_3(T_3)$  indicates that the depression of the N:M ratio for  $T_3(T_4)$  by  $T_4$  is not caused by saturation of nuclear receptors by  $T_3$  or  $T_4$ .

*Physiological alterations in anterior pituitary  $T_4$  5'-monodeiodination.* Anterior pituitary 5'-monodeiodination appears to be markedly increased in hypothyroid rats. This is in contrast to hepatic  $T_4$  5'-monodeiodination, which is reduced under similar circumstances (16). This observation is most intriguing and could be explained in several ways. First, it is conceivable that the increased oxygen consumption of the hypothyroid pituitary, possibly a reflection of increased TSH synthesis by the thyrotrophs, is somehow an important factor in the regulation of  $T_4$  5'-monodeiodination (29). Increased  $\text{O}_2$  consumption in liver is associated with hyperthyroidism and an increased rate of  $T_4$  to  $T_3$  conversion (16). Secondly, Surks and DeFesi (30) have indicated that in chronically hypothyroid rats there is approximately a fourfold increase in the number of thyrotrophs. This increase could explain the increment in  $T_4$  to  $T_3$  conversion if one assumed that this conversion reaction occurred predominantly in the thyrotroph population. At present we have no data on this question. Samuels and Tsai (31) have not observed significant  $T_4$  to  $T_3$  conversion in GH-1 cells grown in culture. Neither has Gershengorn (32) reported  $T_4$  to  $T_3$  conversion in mouse thyrotroph tumor cells in short-term culture. Therefore, both tumors may be inappropriate models for the  $T_4$  to  $T_3$  conversion process in normal pituitary. The increase in activity of  $T_4$  5'-monodeiodination in hypothyroid rats is accompanied by a higher N:M ratio for  $T_3(T_3)$  when compared with controls in the same experiment. The differences in the quantities of  $T_3$  in normal and hypothyroid pituitaries would not seem to be great enough in the context of Table IV to produce this change. The N:M  $T_3(T_3)$  ratio in hypothyroid pituitaries of 0.84 is not significantly higher than the value of 0.45 in the entire group of normal pituitaries.

This may well be due to the large variation between results of experiments done at different times referred to above. If the N:M T<sub>3</sub>(T<sub>4</sub>) ratios are systematically higher than normal in hypothyroid rats, as is suggested by the data in Table VI, this could be explained by an increase in nuclear T<sub>3</sub> receptor caused by lack of tonic suppression of T<sub>3</sub> receptor synthesis or assembly. Samuels et al. (33) have reported that about one-half of the nuclear T<sub>3</sub> receptors in GH-1 cells are depletable by incubation with T<sub>3</sub>, presumably caused by a decreased synthetic rate of receptor. This hypothesis finds further support in the fact that the N:M ratio for T<sub>3</sub>(T<sub>4</sub>) in the T<sub>4</sub>-treated animals was significantly less than that in euthyroid rats (Table VI). Another possible explanation is that there are different amounts of nuclear T<sub>3</sub> receptor per milligram DNA in different populations of pituitary cells (e.g., thyrotrophs as opposed to somatotrophs), and that the alteration in the cell population of the pituitary gland under hypothyroid conditions is sufficient to result in a change in the N:M T<sub>3</sub>(T<sub>4</sub>). Further investigation will be required to resolve these questions.

Previous studies by Kaplan and Utiger (16) demonstrate that injection of 10 μg T<sub>4</sub>/d for 5 d causes a two- to threefold increase in hepatic 5'-monodeiodination. In anterior pituitary tissue, the effect is opposite. T<sub>4</sub> 5'-monodeiodination is suppressed under these circumstances, and the short time required for this change suggests that this is not due to depletion of thyrotrophs but to an alteration in pituitary cell function. Despite the fact that serum T<sub>4</sub> and T<sub>3</sub> concentrations are higher in T<sub>4</sub>-treated animals, the data in Tables IV and V suggest that this cannot explain the phenomenon because pituitary T<sub>4</sub> is only a small fraction of the T<sub>4</sub> in the system. Both of these physiological observations, namely, stimulation of T<sub>4</sub> 5'-monodeiodination in hypothyroidism and its suppression in hyperthyroidism, have been observed by Kaplan in pituitary homogenates (34).

A third physiological situation in which hepatic and pituitary T<sub>4</sub> 5'-monodeiodination differ is that of fasting. Hepatic T<sub>4</sub> 5'-monodeiodination in the rat is inhibited to about 50% of control during fasting (8, 19, 22), whereas there appears to be no effect on pituitary 5'-monodeiodination in vitro (35).<sup>2</sup> It has been suggested that the suppression of hepatic T<sub>4</sub> 5'-monodeiodination in fasted rats is caused by depletion of a required cytosolic cofactor, probably GSH (19, 36, 37). Thus, even though GSH concentrations are reportedly lower in pituitary than in liver (38), depletion may occur less readily (37). The maintenance of normal pituitary T<sub>4</sub> 5'-monodeiodination in the fasting state in man

could partially explain why TSH concentrations do not rise when T<sub>4</sub> to T<sub>3</sub> conversion is reduced and plasma T<sub>3</sub> falls (39-43). However, in the rat, the predominant effect of fasting on the thyroid axis is to suppress TSH, suggesting that a major alteration in thyroid status is achieved through the hypothalamus as well as through alterations in peripheral T<sub>4</sub> to T<sub>3</sub> conversion (8, 44).

*Effect of TRH on T<sub>4</sub> 5'-monodeiodination.* Early studies by Reichlin et al. (45) demonstrate that transplantation of pituitary tissue into the anterior chamber of the eye results in a decrease in the amount of T<sub>3</sub> derived from injected T<sub>4</sub> in that tissue. They suggest that a hypothalamic factor may be required to stimulate T<sub>4</sub> 5'-monodeiodination. Because TRH is a likely candidate for such a hormone, it is of interest that this compound does not appear to affect T<sub>4</sub> to T<sub>3</sub> conversion or nuclear T<sub>3</sub> binding in this system in amounts known to affect TSH release. Therefore, even though there may be mechanisms by which hypothalamic hormones can alter T<sub>4</sub> to T<sub>3</sub> conversion, it would not appear that this is a direct and immediate effect of TRH.

In summary, these results extend our earlier in vivo studies and demonstrate clear effects of thyroid status and iopanoic acid on pituitary T<sub>4</sub> to T<sub>3</sub> conversion. The ability to study both T<sub>4</sub> to T<sub>3</sub> conversion and nuclear T<sub>3</sub> binding simultaneously in vitro without the complex techniques and assumptions required for in vivo studies provides obvious advantages for the investigation of the variables involved in this process in this tissue. Qualitative differences are found in the regulation of T<sub>4</sub> to T<sub>3</sub> conversion in this organ when compared with the liver. These differences may have an important physiological role in TSH regulation. Because the thyrotroph is responsible for maintenance of the euthyroid state, it would be appropriate for this cell to be the most active of those in the pituitary with respect to T<sub>4</sub> to T<sub>3</sub> conversion. This is one conclusion that can be drawn from Table VI. Further studies will be required to resolve the uncertainties regarding the cellular regulation of T<sub>4</sub> to T<sub>3</sub> conversion in this unique tissue which appears to derive at least one-half of its nuclear T<sub>3</sub> from local T<sub>4</sub> 5'-monodeiodination.

## APPENDIX

The following results of a typical experiment are provided to allow the reader to assess the precision and accuracy of the primary data (4). The results are the mean ± SD of the individual results of triplicate samples after a 3-h incubation of normal rat anterior pituitary fragments with 0.14 ng/ml medium T<sub>3</sub> and 3.8 ng/ml medium T<sub>4</sub>. The medium volume is 400 μl.

1. Pituitary wet weight	8.9 ± 0.7 mg/flask	
2. Medium [ <sup>131</sup> I]T <sub>3</sub> (TCA precipitable)		1,267 ± 87 cp5m/μl
3. Medium [ <sup>125</sup> I]T <sub>4</sub> (TCA precipitable)		22,694 ± 1,499 cp5m/μl

<sup>2</sup>Note added in proof. Kaplan has found a small but statistically significant reduction in T<sub>4</sub> 5'-monodeiodination rates in anterior pituitary homogenates from fasted rats (45).

4. Medium [ <sup>125</sup> I]T <sub>3</sub>	
(a) Total [ <sup>125</sup> I] in the "T <sub>3</sub> spot" of the paper chromatograph of the Sepharose eluate of 200 μl of medium as determined by chemical staining and [ <sup>131</sup> I]T <sub>3</sub> counts (postincubation)	19,193 ± 693 cp5m/200 μl
(b) Counts of <sup>125</sup> I in the T <sub>3</sub> spot due to crossover (16% of the [ <sup>131</sup> I]T <sub>3</sub> counts). These counts are higher than actually observed on the strip because they have been corrected for decay to zero time. (This portion of the experiment was not counted until 1–2 wk had elapsed.)	10,764 ± 256 cp5m/200 μl
(c) Net [ <sup>125</sup> I]T <sub>3</sub> (line 4a–line 4b)	9,774 ± 864 cp5m/200 μl
5. Recovery of [ <sup>131</sup> I]T <sub>3</sub> in the T <sub>3</sub> spot of line 4a	27 ± 1%
6. Total [ <sup>125</sup> I]T <sub>3</sub> in the medium (line 4c ÷ line 5 ÷ 200 μl)	181 ± 16 cp5m/μl
7. [ <sup>125</sup> I]T <sub>3</sub> /[ <sup>125</sup> I]T <sub>4</sub> ([ <sup>125</sup> I]T <sub>3</sub> contamination)	0.79 ± 0.02%
Nuclear T <sub>3</sub> (counts corrected for paper background)	
8. [ <sup>131</sup> I]T <sub>3</sub>	9,597 ± 1,478 cp5m
9. [ <sup>131</sup> I]T <sub>3</sub>	1,083 ± 175 cp5m/mg
10. [ <sup>125</sup> I]T <sub>3</sub> (corrected for <sup>131</sup> I crossover)	6,523 ± 965 cp5m
11. [ <sup>125</sup> I]T <sub>3</sub>	735 ± 99 cp5m/mg
N:M ratios	
12. [ <sup>131</sup> I]T <sub>3</sub> (line 9 ÷ line 2)	0.86 ± 0.13 cpm/mg
13. [ <sup>125</sup> I]T <sub>3</sub> (line 11 ÷ line 6)	4.08 ± 0.58 cpm/mg
14. R (N:M [ <sup>125</sup> I]T <sub>3</sub> :N:M [ <sup>131</sup> I]T <sub>3</sub> ) (line 13 ÷ line 12)	4.78 ± 0.32
Other calculations of interest	
15. Fraction of total [ <sup>131</sup> I]T <sub>3</sub> in the flask found in the nuclei (line 8 ÷ line 2 ÷ 400 μl)	1.9%
16. Counts of [ <sup>125</sup> I]T <sub>3</sub> expected in the nuclei in the absence of [ <sup>125</sup> I]T <sub>4</sub> 5'-mono-deiodination (line 15 × line 7 × line 3 × 400 μl)	1,363 cp5m
17. Excess of counts of [ <sup>125</sup> I]T <sub>3</sub> observed over that derived from [ <sup>125</sup> I]T <sub>3</sub> contamination of the medium (lines 10–16)	5,160 cp5m
18. Nuclear [ <sup>125</sup> I]T <sub>4</sub>	5,949 ± 1,091 cp5m
19. Estimated maximum nuclear [ <sup>125</sup> I]T <sub>3</sub> due to artifactual deiodination of nuclear [ <sup>125</sup> I]T <sub>4</sub> during paper chromatography (0.4% of line 18, see reference 6). (Line 10 was not corrected for this small artifact.)	24 cp5m

#### ACKNOWLEDGMENTS

We gratefully acknowledge Ms. Anne Duli for expert help in manuscript preparation.

This work was supported by grants AM 18616, 1 F32 AM 05826, and 5-F32-AM 05553 from the National Institute of Arthritis, Metabolism, and Digestive Diseases; Biomedical Research Support grant S07 RR05489-16 from the National Institutes of Health, Division of Research Resources, and a grant from the William F. Milton Fund.

#### REFERENCES

1. Silva, J. E., and P. R. Larsen. 1977. Pituitary nuclear 3,5,3'-triiodothyronine and thyrotropin secretion: an explanation for the effect of thyroxine. *Science (Wash. D. C.)*. **198**: 617–620.
2. Silva, J. E., and P. R. Larsen. 1978. Contributions of plasma triiodothyronine and local thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine receptor saturation in pituitary, liver and kidney of hypothyroid rats. Further evidence relating saturation of pituitary nuclear triiodothyronine receptors and the acute inhibition of thyroid-stimulating hormone release. *J. Clin. Invest.* **61**: 1247–1259.
3. Silva, J. E., T. E. Dick, and P. R. Larsen. 1978. The contribution of local tissue thyroxine monodeiodination to the nuclear 3,5,3'-triiodothyronine in pituitary, liver and kidney of euthyroid rats. *Endocrinology*. **103**: 1196–1207.
4. Silva, J. E., M. M. Kaplan, R. G. Cheron, T. E. Dick, and P. R. Larsen. 1978. Thyroxine to 3,5,3'-triiodothyronine conversion by rat anterior pituitary and liver. *Metab. Clin. Exp.* **27**: 1601–1607.
5. Oppenheimer, J. H., R. Squef, M. I. Surks, and H. Haver. 1963. Binding of thyroxine by serum proteins evaluated by equilibrium dialysis and electrophoretic techniques. Alterations in nonthyroidal illness. *J. Clin. Invest.* **42**: 1769–1776.
6. Larsen, P. R. 1971. Technical aspects of the estimation of triiodothyronine in human serum: evidence of conversion of thyroxine to triiodothyronine during assay. *Metab. Clin. Exp.* **20**: 609–624.
7. Zimmerman, C. J., M. Izumi, and P. R. Larsen. 1978. Isolation of labeled triiodothyronine from serum using affinity chromatography: application to the estimation of the peripheral T<sub>4</sub> to T<sub>3</sub> conversion in rats. *Metab. Clin. Exp.* **27**: 303–313.
8. Kaplan, M. M., and R. D. Utiger. 1978. Iodothyronine metabolism in rat liver homogenates. *J. Clin. Invest.* **61**: 459–471.
9. Abrams, G. M., and P. R. Larsen. 1973. Triiodothyronine and thyroxine in the serum and thyroid glands of iodine-deficient rats. *J. Clin. Invest.* **52**: 2522–2531.
10. Larsen, P. R. 1972. Direct immunoassay of triiodothyronine in human serum. *J. Clin. Invest.* **51**: 1939–1949.
11. Larsen, P. R., J. Dockalova, D. Sipula, and F. M. Wu. 1973. Immunoassay of thyroxine in unextracted human serum. *J. Clin. Endocrinol. Metab.* **37**: 177–182.
12. Weeke, J., and H. Orskov. 1973. Synthesis of <sup>125</sup>I mono-labelled 3,5,3'-triiodothyronine and thyroxine of maximum specific activity for radioimmunoassay. *Scan. J. Clin. Lab. Invest.* **32**: 357–360.
13. Oppenheimer, J. H., H. L. Schwartz, D. Koerner, and M. I. Surks. 1974. Limited binding capacity sites for L-triiodothyronine in rat liver nuclei. *J. Clin. Invest.* **53**: 768–777.
14. Schadow, A. R., M. I. Surks, H. L. Schwartz, and J. H. Oppenheimer. 1972. Specific triiodothyronine binding sites in the anterior pituitary of the rat. *Science (Wash. D. C.)*. **176**: 1252–1254.

15. Gordon, A., and O. Spira. 1975. Triiodothyronine binding in rat anterior pituitary, posterior pituitary, median eminence and brain. *Endocrinology*. **96**: 1357-1365.
16. Kaplan, M. M., and R. D. Utiger. 1978. Iodothyronine metabolism in liver and kidney homogenates from hyperthyroid and hypothyroid rats. *Endocrinology*. **103**: 156-161.
17. Balsam, A., and S. H. Ingbar. 1978. The influence of fasting, diabetes, and several pharmacological agents on the pathways of thyroxine metabolism in rat liver. *J. Clin. Invest.* **62**: 415-424.
18. Harris, A. R. C., S. L. Fang, A. G. Vagendakis, and L. E. Braverman. 1978. Effect of starvation, nutriment replacement, and hypothyroidism on *in vitro* hepatic T<sub>4</sub> to T<sub>3</sub> conversion in the rat. *Metab. Clin. Exp.* **27**: 1680-1689.
19. Kaplan, M. M. 1979. Subcellular alterations causing reduced hepatic thyroxine 5'-monodeiodinase activity in fasted rats. *Endocrinology* **104**: 58-64.
20. Hillier, A. P. 1972. Deiodination of thyroid hormones by the perfused rat liver. *J. Physiol. (Lond.)*. **222**: 475-485.
21. Visser, T. J., I. Van der Does-Tobé, R. Docter, and G. Hennemann. 1975. Conversion of thyroxine into triiodothyronine by rat liver homogenate. *Biochem. J.* **150**: 489-493.
22. Chopra, I. J. 1977. A study of extrathyroidal conversion of thyroxine (T<sub>4</sub>) to 3,3',5'-triiodothyronine (T<sub>3</sub>) *in vitro*. *Endocrinology*. **101**: 453-463.
23. Chopra, I. J., H. E. Carlson, and D. H. Solomon. 1978. Comparison of inhibitory effects of 3,5,3'-triiodothyronine (T<sub>3</sub>), thyroxine (T<sub>4</sub>), 3,3',5'-triiodothyronine (rT<sub>3</sub>), and 3,3'-diiodothyronine (T<sub>2</sub>) on thyrotropin-releasing hormone-induced release of thyrotropin in the rat *in vitro*. *Endocrinology*. **103**: 393-402.
24. Galton, V. A. 1976. The metabolism of thyroid hormones in rat pituitary. *In* Thyroid Research. Proceedings of the 7th International Thyroid Conference, Boston. J. Robbins, and L. E. Braverman, editors. Elsevier, Amsterdam. 251-254.
25. Larsen, P. R., and R. D. Frumess. 1977. Comparison of the biological effects of thyroxine and triiodothyronine in the rat. *Endocrinology*. **100**: 980-988.
26. Larsen, P. R., T. E. Dick, B. P. Markovitz, M. M. Kaplan, and T. G. Gard. 1979. Inhibition of intrapituitary thyroxine to 3,5,3'-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats. *J. Clin. Invest.* **64**: 117-128.
27. Frumess, R. D., and P. R. Larsen. 1975. Correlation of serum triiodothyronine (T<sub>3</sub>) and thyroxine (T<sub>4</sub>) with biologic effects of thyroid hormone replacement in propylthiouracil-treated rats. *Metab. Clin. Exp.* **24**: 547-554.
28. Oppenheimer, J. H., H. L. Schwartz, and M. I. Surks. 1974. Tissue differences in the concentration of triiodothyronine nuclear binding sites in the rat: liver, kidney, pituitary, heart, brain, spleen and testis. *Endocrinology*. **95**: 897-903.
29. Levey, H. A., and S. Roberts. 1957. Influence of thyroid function on the metabolism of the anterior pituitary gland. *Am. J. Physiol.* **189**(1): 86-90.
30. Surks, M. I., and C. R. DeFesi. 1977. Determination of the cell number of each cell type in the anterior pituitary of euthyroid and hypothyroid rats. *Endocrinology*. **101**: 946-958.
31. Samuels, H. H., and J. S. Tsai. 1973. Thyroid hormone action in cell culture: demonstration of nuclear receptors in intact cells and isolated nuclei. *Proc. Natl. Acad. Sci. U. S. A.* **70**: 3488-3492.
32. Gershengorn, M. C. 1978. Regulation of thyrotropin production by mouse pituitary thyrotropic tumor cells *in vitro* by physiological levels of thyroid hormones. *Endocrinology*. **102**: 1122-1128.
33. Samuels, H. H., F. Stanley, and L. E. Shapiro. 1976. Dose-dependent depletion of nuclear receptors by L-triiodothyronine: evidence for a role in induction of growth hormone synthesis in cultures GH<sub>1</sub> cells. *Proc. Natl. Acad. Sci. U. S. A.* **73**: 3877-3881.
34. Kaplan, M. M. 1978. T<sub>4</sub> to T<sub>3</sub> conversion in rat pituitary homogenate. Program of the 54th Meeting of the American Thyroid Association. 13-16 September 1978, Portland, Oreg. T-6. (Abstr.)
35. Kaplan, M. M. 1980. Thyroxine 5'-monodeiodination in rat anterior pituitary homogenates. *Endocrinology*. In press.
36. Balsam, A., and S. H. Ingbar. 1978. The mechanism of regulation of triiodothyronine (T<sub>3</sub>) generation from thyroxine (T<sub>4</sub>) in liver of normal and fasted rats. *Clin. Res.* **26**: 489A.
37. Visser, T. J. 1978. A tentative review of recent *in vitro* observations of the enzymatic deiodination of iodothyronines and its possible physiological implications. *Mol. Cell. Endocr.* **10**: 241-247.
38. Owens, C. W. I., and R. V. Belcher. 1965. A colorimetric micro-method for the determination of glutathione. *Biochem. J.* **94**: 705-711.
39. Portnay, G. I., J. T. O'Brien, J. Bush, A. G. Vagenakis, F. Azizi, R. A. Arky, S. H. Ingbar, and L. E. Braverman. 1974. The effect of starvation on the concentration and binding of thyroxine and triiodothyronine in serum and on the response to TRH. *J. Clin. Endocrinol. Metab.* **39**: 191-194.
40. Croxson, M. S., T. D. Hall, O. A. Kletzky, J. E. Jaramillo, and J. T. Nicoloff. 1977. Decreased serum thyrotropin induced by fasting. *J. Clin. Endocrinol. Metab.* **45**: 560-568.
41. Carlson, H. E., E. J. Drenick, I. J. Chopra, and J. M. Hershman. 1977. Alterations in basal and TRH-stimulated serum levels of thyrotropin, prolactin and thyroid hormones in starved obese men. *J. Clin. Endocrinol. Metab.* **45**: 707-713.
42. Vinik, A. I., W. J. Kalk, H. McLaren, and M. Paul. 1975. Fasting blunts the TSH response to synthetic thyrotropin-releasing hormone (TRH). *J. Clin. Endocrinol. Metab.* **40**: 509-511.
43. Azizi, F. 1978. Effect of dietary composition of fasting-induced changes in serum thyroid hormones and thyrotropin. *Metab. Clin. Exp.* **27**: 935-942.
44. Campbell, G. A., M. Kurcz, S. Marshall, and J. Meites. 1977. Effects of starvation in rats on serum levels of follicle stimulating hormone, luteinizing hormone, thyrotropin, growth hormone and prolactin; response to LH-releasing hormone and thyrotropin-releasing hormone. *Endocrinology*. **100**: 580-587.
45. Reichlin, S., E. M. Volpert, and S. H. Werner. 1966. Hypothalamic influence on thyroxine monodeiodination by rat anterior pituitary gland. *Endocrinology*. **78**: 302-306.